Celltrion Healthcare | Sustainability Performance
Distributes biopharmaceutical products to global healthcare providers and commercial partners.
1999
South Korea
51 - 200 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#8274
Overallⓘ#113
in South Koreaⓘ#193
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Celltrion Healthcare Inc (post2023 CelltrionCelltrion Healthcare merger creating consolidated Celltrion), Korean major biosimilar manufacturer (Remsima/Inflectra infliximab, Truxima rituximab, Yuflyma adalimumab), has faced multiple international class actions over alleged inadequate disclosure of US/European biosimilar customer demand normalization, plus the historic 2023 Korean FSC merger integration challenges affecting Korean institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
1
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.